Navigation Links
CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process That Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference
Date:6/16/2009

VIENNA, Va., June 16 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM) announced today that Eyal Talor, Ph.D., Senior Vice President of Research and Manufacturing at CEL-SCI, has accepted an invitation to be a featured speaker at the 5th Annual Aseptic Processing of Sterile Drug Products Conference to be held June 17th - 19th. The Conference, sponsored by The Institute of Validation Technology (IVT), takes place at the Sheraton National Hotel in Arlington, VA. At the workshop titled "Aseptic Facility Design Fundamentals - Cold Fill/Finish Design for a Biologic, Liquid Injectable", Dr. Talor will discuss the Company's plans to launch a unique manufacturing process that could allow drugs using stem cell technology and other biological products to maintain their potency through the entire manufacturing process, as well as enhance the shelf life of these drugs.

The availability of this unique aseptic filling process developed by CEL-SCI may also significantly accelerate the time to market by eliminating complicated, costly and time consuming validation studies and tests required when these products are filled at room temperature. This process is also likely to save money in the production of follow-on biologics and biosimilars (the general equivalent of generics in the biological arena) likely to be approved in the U.S. soon.

CEL-SCI's new state-of-the-art manufacturing facility near Baltimore, Maryland, where CEL-SCI plans to manufacture its lead cancer product Multikine(R), will be offering this service to outside companies on a contract basis. The facility will allow CEL-SCI to perform aseptic filling of small volume parenteral drug products.

The Company will employ a process known as "true cold" +4 degrees Celsius Aseptic Filling for products derived from stem cell technology, biotechn
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. CEL-SCI Expands Testing of Its Vaccine to Determine Efficacy Against More Virulent Strain of H1N1 Swine and Other Influenza Viruses
2. CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results
3. CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa
4. CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
5. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
6. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
7. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
8. CEL-SCI Corporation Releases Letter to Shareholders
9. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
10. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
11. Scientists advance safety of nanotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 Allscripts (Nasdaq: MDRX ... financial results for the three and six months ... opens on Monday, January 11, 2010. Allscripts management ... discuss the company,s earnings and other information at ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, Allscripts ...
(Date:12/16/2009)... Dec. 16 As a result of C3: ... new peer reviewed cancer research program is included in ... ,, This new cancer research program will research cancers, ... breast, prostate, lung and ovarian cancer research programs run ... ,, The $15 million in funding for ...
(Date:12/16/2009)... seven that increase susceptibility to disease , , WEDNESDAY, ... with increased susceptibility to leprosy have been identified ... researchers, who analyzed more than 10,000 DNA samples ... said their discovery highlights the important role that ... of leprosy. , "Though leprosy is not common, ...
(Date:12/16/2009)... that could help ease health and environmental concerns about ... technology for changing the behavior of nanoparticles in municipal ... environment. Their study was published in ACS, journal ... the UK Centre for Ecology and Hydrology and colleagues ... of nanoparticles particles less than 1/1000th the width ...
(Date:12/16/2009)... Immune-boosting, Newborn-Safe Skin Care Products from Episencial Offers Planet-Friendly Organics, ... Available , ... Los Angeles, CA ... values now have an authentic, affordable choice in all natural ... launches its eponymous product line for young children featuring the ...
Breaking Medicine News(10 mins):Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Leprosy Genes Identified 2Health News:Behavior modification could ease concerns about nanoparticles 2Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 2Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 3Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 4Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 5
... Aug. 21 The following was,released by the ... Institute - founder of a public policy,research organization ... Melinna Giannini, Founder & CEO, ABC Coding ... platform that helps connect health care,professionals with the ...
... industry best practices, meets new ... state government ... consulting,practice Halleland Health Consulting announces the development of a,comprehensive ... (PBMs) seeking the level of excellence required,by the Utilization ...
... Bruce Bodaken,Chairman, President & CEO of Blue Shield ... Rocky Mountain Roundtable on Health, Wellness and,Prevention at the ... 2008, 9:30 a.m. MDT at Boettcher Hall in the ... of wellness programs,in health reform, and the ways in ...
... No. 1352 on the 2008 Inc. 5,000 list, experiences three-year ... sales growth of ... Vigilan,as No. 1352 on its annual ranking of the 5,000 fastest-growing ... look at,one of the most important segments in the economy -- ...
... International,Center today announced that its board member, former ... Meridian,s new Global Health,Program. The Global Health Program ... include world affairs public briefings and conferences, U.S.,State ... activities., "Today, 79% of people suffering from ...
... 21 The Pancreatic Cancer,Action Network ( http://www.pancan.org ... comprehensive way through research, patient support,community outreach and ... loss of NFL,Hall of Fame member Gene Upshaw., ... condolences to the,Upshaw family and the entire NFL ...
Other Medicine News:Health News:Halleland Health Consulting Establishes URAC Accreditation Program 2Health News:Blue Shield of California CEO to Speak at Democratic Convention Host Committee's Health Roundtable in Denver 2Health News:Vigilan Recognized as One of the Fastest-Growing Private Companies in the U.S. 2Health News:Former U.S. Assistant Surgeon General, Dr. Susan Blumenthal, to Lead Meridian International Center's Global Health Program 2Health News:The Pancreatic Cancer Action Network is Saddened by the Death of NFL Hall of Fame Member Gene Upshaw 2
(Date:12/16/2009)... BAY, Wis., Dec. 16 EuroPharma, ... Biotech for the use of super absorbency ... multiple EuroPharma formulations. The exclusive distribution ... the health food store channel and professional ... doctors, and clinics. BCM-95® is a ...
(Date:12/16/2009)... -- RealMed has been ranked the #1 ... 2009 Top 20 Best in KLAS Awards: ... is a dynamic revenue cycle management solution ... healthcare providers and all payers. ... in vendor performance measurement in the software, ...
(Date:12/16/2009)... MALVERN, Pa., Dec. 16 ... flexible financing solutions ... objectives and meet deadlines defined within the ... Reinvestment Act (ARRA). Featuring zero-percent ... enable organizations to defer up-front payments associated ...
Breaking Medicine Technology:EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4Patients Taking VIMOVO 28TM 29 Showed a Decrease in Incidence of NSAID Associated Ulcers 5553 1Patients Taking VIMOVO 28TM 29 Showed a Decrease in Incidence of NSAID Associated Ulcers 5553 2Patients Taking VIMOVO 28TM 29 Showed a Decrease in Incidence of NSAID Associated Ulcers 5553 3Patients Taking VIMOVO 28TM 29 Showed a Decrease in Incidence of NSAID Associated Ulcers 5553 4Patients Taking VIMOVO 28TM 29 Showed a Decrease in Incidence of NSAID Associated Ulcers 5553 5DigitalPersona Announces Windows 7 Support for Its Enterprise Developer and Consumer Products 10411 1DigitalPersona Announces Windows 7 Support for Its Enterprise Developer and Consumer Products 10411 2DigitalPersona Announces Windows 7 Support for Its Enterprise Developer and Consumer Products 10411 3Drugs for Irritable Bowel Might Increase Cancer Risk 59736 1
... QMed, Inc.,(Nasdaq: QMED ) today announced it ... the Centers for Medicare and Medicaid Services (CMS) ... Northern,California., In 2002, The CMS selected 15 ... coordinated care services to Medicare fee-for-service,beneficiaries with complex ...
... Some Emerging Therapies Hold Promise, Enbrel Will Remain the Clinical ... ... Decision Resources, WALTHAM, Mass., April 7, 2008 ... focusing on,pharmaceutical and healthcare issues, finds that a drug,s effect on,inhibiting/slowing ...
Other Medicine Technology:QMed, Inc. Receives 2-Year Extension of Medicare Coordinated Care Demonstration Project by CMS 2Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis 2Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis 3
... Varicella-Zoster Virus (VZV) IgG Enzyme-Linked Immunosorbent Assay ... quantitative determination of IgG antibody to VZV ... may be used for the determination of ... may be used to demonstrate seroconversion or ...
... Scientific, Inc. Mumps IgG ELISA test system ... Mumps IgG antibody in human serum. When ... of this test, together with other clinical ... immune status, and/or aid in the diagnosis ...
... The Trinity Biotech Mumps IgM ... intended for the qualitative detection ... serum to Mumps for the ... performance characteristics of this kit ...
The CALBIOTECH, INC. (CBI), Mumps IgM ELISA tests system is an enzyme linked immunosorbent assay (ELISA) for the detection of IgM class antibodies to Mumps in human serum or plasma....
Medicine Products: